Cyclic peptides as drugs for intracellular targets: the next frontier in peptide therapeutic development.

Developing macrocyclic peptides that can reach intracellular targets is a significant challenge. This review discusses the most recent strategies used to develop cell permeable cyclic peptides that maintain binding to their biological target inside the cell.  Macrocyclic peptides are unique from small molecules because traditional calculated physical properties are unsuccessful for predicting cell membrane permeability. Peptide synthesis and experimental membrane permeability is the only strategy that effectively differentiates between cell permeable and cell impermeable molecules. Discussed are chemical strategies, including backbone N-methylation and stereochemical changes, which have produced molecular scaffolds with improved cell permeability. However, these improvements often come at the expense of biological activity as chemical modifications alter the peptide conformation, frequently impacting the compound's ability to bind to the target. Highlighted is the most promising approach, which involves side chain alterations that improve cell permeability without impact binding events.

[1]  Jan Baumbach,et al.  From single drug targets to synergistic network pharmacology in ischemic stroke , 2019, Proceedings of the National Academy of Sciences.

[2]  K. Hoehn,et al.  Delivering bioactive cyclic peptides that target Hsp90 as prodrugs , 2019, Journal of enzyme inhibition and medicinal chemistry.

[3]  Lichun Sun,et al.  Drug discovery and drug marketing with the critical roles of modern administration. , 2018, American journal of translational research.

[4]  Luis M Liz-Marzán,et al.  Cellular Uptake of Nanoparticles versus Small Molecules: A Matter of Size. , 2018, Accounts of chemical research.

[5]  Joshua A. Kritzer,et al.  Cell Penetration Profiling Using the Chloroalkane Penetration Assay. , 2018, Journal of the American Chemical Society.

[6]  H. Kessler,et al.  Enhancing Oral Bioavailability of Cyclic RGD Hexa-peptides by the Lipophilic Prodrug Charge Masking Approach: Redirection of Peptide Intestinal Permeability from a Paracellular to Transcellular Pathway. , 2018, Molecular pharmaceutics.

[7]  A. Yudin,et al.  Development of Endocyclic Control Elements for Peptide Macrocycles. , 2018, Journal of the American Chemical Society.

[8]  Jason E Gestwicki,et al.  Inhibitors of protein-protein interactions (PPIs): an analysis of scaffold choices and buried surface area. , 2018, Current opinion in chemical biology.

[9]  S. McAlpine,et al.  Converting polar cyclic peptides into membrane permeable molecules using N‐methylation , 2018 .

[10]  Daniel J. Sindhikara,et al.  High throughput evaluation of macrocyclization strategies for conformer stabilization , 2018, Scientific Reports.

[11]  Vasanthanathan Poongavanam,et al.  Impact of Dynamically Exposed Polarity on Permeability and Solubility of Chameleonic Drugs Beyond the Rule of 5. , 2018, Journal of medicinal chemistry.

[12]  Ji Hoon Lee,et al.  Comparison of Cell Permeability of Cyclic Peptoids and Linear Peptoids. , 2018, ACS combinatorial science.

[13]  D. Craik,et al.  Conformational Flexibility Is a Determinant of Permeability for Cyclosporin. , 2018, The journal of physical chemistry. B.

[14]  S. McAlpine,et al.  Improving the Cell Permeability of Polar Cyclic Peptides by Replacing Residues with Alkylated Amino Acids, Asparagines, and d-Amino Acids. , 2018, Organic letters.

[15]  Jayanta Chatterjee,et al.  Increasing the bioactive space of peptide macrocycles by thioamide substitution , 2018, Chemical science.

[16]  K. Goss,et al.  Predicting apparent passive permeability of Caco-2 and MDCK cell-monolayers: A mechanistic model , 2017, PloS one.

[17]  S. McAlpine,et al.  Synthesis and Structure–Activity Relationships of Inhibitors That Target the C-Terminal MEEVD on Heat Shock Protein 90 , 2017, ACS medicinal chemistry letters.

[18]  A. Mathiowetz,et al.  Discovery of Potent and Orally Bioavailable Macrocyclic Peptide-Peptoid Hybrid CXCR7 Modulators. , 2017, Journal of medicinal chemistry.

[19]  A. Ganesan,et al.  Systematic Analysis of the Relationship among 3D Structure, Bioactivity, and Membrane Permeability of PF1171F, a Cyclic Hexapeptide with Paralyzing Effects on Silkworms. , 2017, The Journal of organic chemistry.

[20]  Alexandre M J J Bonvin,et al.  SpotOn: High Accuracy Identification of Protein-Protein Interface Hot-Spots , 2017, Scientific Reports.

[21]  James C. Collins,et al.  The Current State of Peptide Drug Discovery: Back to the Future? , 2017, Journal of medicinal chemistry.

[22]  Horst Kessler,et al.  Improving oral bioavailability of cyclic peptides by N-methylation. , 2017, Bioorganic & medicinal chemistry.

[23]  Jolene L. Lau,et al.  Therapeutic peptides: Historical perspectives, current development trends, and future directions. , 2017, Bioorganic & medicinal chemistry.

[24]  C. Heinis,et al.  Cyclic peptide therapeutics: past, present and future. , 2017, Current opinion in chemical biology.

[25]  D. Mochly‐Rosen,et al.  Peptides and peptidomimetics as regulators of protein-protein interactions. , 2017, Current opinion in structural biology.

[26]  Martin J. Stoermer,et al.  Orally Absorbed Cyclic Peptides. , 2017, Chemical reviews.

[27]  T. Vorherr,et al.  Modulation of Oral Bioavailability and Metabolism for Closely Related Cyclic Hexapeptides , 2017, International Journal of Peptide Research and Therapeutics.

[28]  A. Mathiowetz,et al.  Comparative pharmacokinetic profile of cyclosporine (CsA) with a decapeptide and a linear analogue. , 2017, Organic & biomolecular chemistry.

[29]  S. Shuto,et al.  Highly Conformationally Restricted Cyclopropane Tethers with Three-Dimensional Structural Diversity Drastically Enhance the Cell Permeability of Cyclic Peptides. , 2017, Chemistry.

[30]  Yao Wang,et al.  Redefining the Phenotype of Heat Shock Protein 90 (Hsp90) Inhibitors. , 2017, Chemistry.

[31]  Honggang Cui,et al.  Peptide–drug conjugates as effective prodrug strategies for targeted delivery , 2017, Advanced drug delivery reviews.

[32]  A Ganesan,et al.  Oral Administration of Peptide‐Based Drugs: Beyond Lipinski's Rule , 2016, ChemMedChem.

[33]  Chad E. Townsend,et al.  Passive Membrane Permeability in Cyclic Peptomer Scaffolds Is Robust to Extensive Variation in Side Chain Functionality and Backbone Geometry. , 2016, Journal of medicinal chemistry.

[34]  T. Kodadek,et al.  Cell-Permeable Peptides Containing Cycloalanine Residues. , 2016, Angewandte Chemie.

[35]  Matthew R. Naylor,et al.  Stereochemistry Balances Cell Permeability and Solubility in the Naturally Derived Phepropeptin Cyclic Peptides. , 2016, ACS medicinal chemistry letters.

[36]  A. Liguori,et al.  N-Methylated α-Amino Acids And Peptides: Synthesis And Biological Activity. , 2016, Mini reviews in medicinal chemistry.

[37]  Serge Zaretsky,et al.  Passive Membrane Permeability of Macrocycles Can Be Controlled by Exocyclic Amide Bonds. , 2016, Journal of medicinal chemistry.

[38]  S. Vajda,et al.  Quantifying the chameleonic properties of macrocycles and other high-molecular-weight drugs. , 2016, Drug discovery today.

[39]  D. Scott,et al.  Small molecules, big targets: drug discovery faces the protein–protein interaction challenge , 2016, Nature Reviews Drug Discovery.

[40]  Paul W. Wojcik,et al.  Peptide-based inhibitors of protein-protein interactions. , 2016, Bioorganic & medicinal chemistry letters.

[41]  Mie Kristensen,et al.  Applications and Challenges for Use of Cell-Penetrating Peptides as Delivery Vectors for Peptide and Protein Cargos , 2016, International journal of molecular sciences.

[42]  S. McAlpine,et al.  The first report of direct inhibitors that target the C-terminal MEEVD region on heat shock protein 90. , 2016, Chemical communications.

[43]  M. Chung,et al.  The Prodrug Approach: A Successful Tool for Improving Drug Solubility , 2015, Molecules.

[44]  Jan Tavernier,et al.  Modulation of Protein–Protein Interactions for the Development of Novel Therapeutics , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[45]  Alessio Ciulli,et al.  Cyclic and Macrocyclic Peptides as Chemical Tools To Recognise Protein Surfaces and Probe Protein–Protein Interactions , 2015, ChemMedChem.

[46]  Alun Jones,et al.  Flexibility versus Rigidity for Orally Bioavailable Cyclic Hexapeptides , 2015, Chembiochem : a European journal of chemical biology.

[47]  D. Murray,et al.  Romidepsin targets multiple survival signaling pathways in malignant T cells , 2015, Blood Cancer Journal.

[48]  Chad E. Townsend,et al.  Going Out on a Limb: Delineating The Effects of β-Branching, N-Methylation, and Side Chain Size on the Passive Permeability, Solubility, and Flexibility of Sanguinamide A Analogues. , 2015, Journal of medicinal chemistry.

[49]  O. Koch,et al.  Strukturbasierte Entwicklung von Protein-Protein-Interaktionsinhibitoren: Stabilisierung und Nachahmung von Peptidliganden , 2015 .

[50]  O. Koch,et al.  Structure-Based Design of Inhibitors of Protein–Protein Interactions: Mimicking Peptide Binding Epitopes , 2015, Angewandte Chemie.

[51]  Matthew P. Jacobson,et al.  Beyond cyclosporine A: conformation-dependent passive membrane permeabilities of cyclic peptide natural products. , 2015, Future medicinal chemistry.

[52]  H. Kessler,et al.  Enantiomeric cyclic peptides with different Caco-2 permeability suggest carrier-mediated transport. , 2015, Chemistry.

[53]  Matthew P Jacobson,et al.  Probing the Physicochemical Boundaries of Cell Permeability and Oral Bioavailability in Lipophilic Macrocycles Inspired by Natural Products. , 2015, Journal of medicinal chemistry.

[54]  Andrew M Watkins,et al.  Structure-based inhibition of protein-protein interactions. , 2015, European journal of medicinal chemistry.

[55]  N. Tsomaia Peptide therapeutics: targeting the undruggable space. , 2015, European journal of medicinal chemistry.

[56]  Yang Wang,et al.  N-terminal and C-terminal modulation of Hsp90 produce dissimilar phenotypes. , 2015, Chemical communications.

[57]  T. A. Hill,et al.  Fixierung cyclischer Peptide: Mimetika von Proteinstrukturmotiven , 2014 .

[58]  D. Fairlie,et al.  Constraining cyclic peptides to mimic protein structure motifs. , 2014, Angewandte Chemie.

[59]  David J. Craik,et al.  Rational design and synthesis of an orally bioavailable peptide guided by NMR amide temperature coefficients , 2014, Proceedings of the National Academy of Sciences.

[60]  D. Craik,et al.  Improving on nature: making a cyclic heptapeptide orally bioavailable. , 2014, Angewandte Chemie.

[61]  J. Wells,et al.  Small-molecule inhibitors of protein-protein interactions: progressing toward the reality. , 2014, Chemistry & biology.

[62]  A. Ganesan,et al.  Total synthesis and biological evaluation of PF1171A, C, F, and G, cyclic hexapeptides with insecticidal activity. , 2014, The Journal of organic chemistry.

[63]  G. Goetz,et al.  EPSA: A Novel Supercritical Fluid Chromatography Technique Enabling the Design of Permeable Cyclic Peptides. , 2014, ACS medicinal chemistry letters.

[64]  Martin J. Stoermer,et al.  Cyclic Penta- and Hexaleucine Peptides without N-Methylation Are Orally Absorbed. , 2014, ACS medicinal chemistry letters.

[65]  J. Bajorath,et al.  Polypharmacology: challenges and opportunities in drug discovery. , 2014, Journal of medicinal chemistry.

[66]  Dima Kozakov,et al.  How Proteins Bind Macrocycles , 2014, Nature chemical biology.

[67]  N. Selner,et al.  Early Endosomal Escape of a Cyclic Cell-Penetrating Peptide Allows Effective Cytosolic Cargo Delivery , 2014, Biochemistry.

[68]  S. McAlpine,et al.  A heat shock protein 90 inhibitor that modulates the immunophilins and regulates hormone receptors without inducing the heat shock response. , 2014, Bioorganic & medicinal chemistry letters.

[69]  Serge Zaretsky,et al.  Exocyclic control of turn induction in macrocyclic peptide scaffolds. , 2013, Chemistry.

[70]  S. Sagan,et al.  Cell‐penetrating peptides: 20 years later, where do we stand? , 2013, FEBS letters.

[71]  Horst Kessler,et al.  N-methylation of peptides and proteins: an important element for modulating biological functions. , 2013, Angewandte Chemie.

[72]  H. Kessler,et al.  N‐Methylierung von Peptiden und Proteinen: ein wichtiges Element für die Regulation biologischer Funktionen , 2013 .

[73]  D. Craik,et al.  The Future of Peptide‐based Drugs , 2013, Chemical biology & drug design.

[74]  I. Khanna Drug discovery in pharmaceutical industry: productivity challenges and trends. , 2012, Drug discovery today.

[75]  Yizhong Zhang,et al.  Optimizing PK properties of cyclic peptides: the effect of side chain substitutions on permeability and clearance(). , 2012, MedChemComm.

[76]  I. Toth,et al.  Peptides as therapeutics with enhanced bioactivity. , 2012, Current medicinal chemistry.

[77]  K. Jolliffe,et al.  Synthesis of sansalvamide A peptidomimetics: triazole, oxazole, thiazole, and pseudoproline containing compounds. , 2012, Tetrahedron.

[78]  J. Ge,et al.  Clinical Use of Aspirin in Treatment and Prevention of Cardiovascular Disease , 2011, Thrombosis.

[79]  Li Di,et al.  Development of a new permeability assay using low-efflux MDCKII cells. , 2011, Journal of pharmaceutical sciences.

[80]  Yizhong Zhang,et al.  On-resin N-methylation of cyclic peptides for discovery of orally bioavailable scaffolds , 2011, Nature chemical biology.

[81]  Hannu Raunio,et al.  Prodrugs—from Serendipity to Rational Design , 2011, Pharmacological Reviews.

[82]  Philippe Roche,et al.  Chemical and structural lessons from recent successes in protein-protein interaction inhibition (2P2I). , 2011, Current opinion in chemical biology.

[83]  Douglas B Kell,et al.  Pharmaceutical drug transport: the issues and the implications that it is essentially carrier-mediated only. , 2011, Drug discovery today.

[84]  Christopher J. White,et al.  Contemporary strategies for peptide macrocyclization. , 2011, Nature chemistry.

[85]  Gert Storm,et al.  Endosomal escape pathways for delivery of biologicals. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[86]  D. Kingston Modern natural products drug discovery and its relevance to biodiversity conservation. , 2011, Journal of natural products.

[87]  H. Kessler,et al.  The effect of multiple N-methylation on intestinal permeability of cyclic hexapeptides. , 2011, Molecular pharmaceutics.

[88]  T. Joh,et al.  Involvement of oxidative stress and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in inflammatory bowel disease , 2011, Journal of clinical biochemistry and nutrition.

[89]  Peter Buchwald,et al.  Small‐molecule protein–protein interaction inhibitors: Therapeutic potential in light of molecular size, chemical space, and ligand binding efficiency considerations , 2010, IUBMB life.

[90]  Li Di,et al.  Coexistence of passive and carrier-mediated processes in drug transport , 2010, Nature Reviews Drug Discovery.

[91]  R. King Biotransformations in Drug Metabolism , 2010 .

[92]  C. Gilon,et al.  The effect of backbone cyclization on PK/PD properties of bioactive peptide-peptoid hybrids: the melanocortin agonist paradigm. , 2010, Bioorganic & medicinal chemistry.

[93]  Christian N. Cunningham,et al.  Mechanistic studies of Sansalvamide A-amide: an allosteric modulator of Hsp90. , 2010, ACS medicinal chemistry letters.

[94]  H. McMahon,et al.  Mechanisms of endocytosis. , 2009, Annual review of biochemistry.

[95]  E. Thines,et al.  Anthranicine, an Unusual Cyclic Hexapeptide from Acremonium sp. A29-2004 , 2009 .

[96]  A. Hopkins Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.

[97]  Ismael Zamora,et al.  The Molecular Basis of CYP2D6-Mediated N-Dealkylation: Balance between Metabolic Clearance Routes and Enzyme Inhibition , 2008, Drug Metabolism and Disposition.

[98]  H. Kessler,et al.  N-methylation of peptides: a new perspective in medicinal chemistry. , 2008, Accounts of chemical research.

[99]  G. Rishton,et al.  Natural products as a robust source of new drugs and drug leads: past successes and present day issues. , 2008, The American journal of cardiology.

[100]  H. Kessler,et al.  Die Verbesserung der oralen Bioverfügbarkeit von Peptiden durch multiple N‐Methylierung: Somatostatin‐Analoga , 2008 .

[101]  J. Brueggen,et al.  Improving oral bioavailability of peptides by multiple N-methylation: somatostatin analogues. , 2008, Angewandte Chemie.

[102]  D. Kell,et al.  Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? , 2008, Nature Reviews Drug Discovery.

[103]  Christopher L. McClendon,et al.  Reaching for high-hanging fruit in drug discovery at protein–protein interfaces , 2007, Nature.

[104]  A. Barabasi,et al.  Drug—target network , 2007, Nature Biotechnology.

[105]  Richard W Roberts,et al.  Design of cyclic peptides that bind protein surfaces with antibody-like affinity. , 2007, ACS chemical biology.

[106]  P. Artursson,et al.  Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers , 2007, Nature Protocols.

[107]  Jian Yang,et al.  Antiplatelet Agents Aspirin and Clopidogrel Are Hydrolyzed by Distinct Carboxylesterases, and Clopidogrel Is Transesterificated in the Presence of Ethyl Alcohol , 2006, Journal of Pharmacology and Experimental Therapeutics.

[108]  Matthew P Jacobson,et al.  Conformational flexibility, internal hydrogen bonding, and passive membrane permeability: successful in silico prediction of the relative permeabilities of cyclic peptides. , 2006, Journal of the American Chemical Society.

[109]  C. Horvath,et al.  Carbonyl- and sulfur-containing analogs of suberoylanilide hydroxamic acid: Potent inhibition of histone deacetylases. , 2006, Bioorganic & medicinal chemistry.

[110]  Matthew P Jacobson,et al.  Testing the conformational hypothesis of passive membrane permeability using synthetic cyclic peptide diastereomers. , 2006, Journal of the American Chemical Society.

[111]  A. Cooke,et al.  MAdCAM‐1 is needed for diabetes development mediated by the T cell clone, BDC‐2·5 , 2005, Immunology.

[112]  L. Vassilev,et al.  Targeting protein–protein interactions for cancer therapy , 2005, Journal of Molecular Medicine.

[113]  M. Butler Natural products to drugs: natural product-derived compounds in clinical trials. , 2005, Natural product reports.

[114]  F. Koehn,et al.  The evolving role of natural products in drug discovery , 2005, Nature Reviews Drug Discovery.

[115]  Péter Csermely,et al.  The efficiency of multi-target drugs: the network approach might help drug design. , 2004, Trends in pharmacological sciences.

[116]  C. Lipinski Lead- and drug-like compounds: the rule-of-five revolution. , 2004, Drug discovery today. Technologies.

[117]  Mark S Butler,et al.  The role of natural product chemistry in drug discovery. , 2004, Journal of natural products.

[118]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[119]  David J Newman,et al.  Natural products as sources of new drugs over the period 1981-2002. , 2003, Journal of natural products.

[120]  S. Jois,et al.  Design of β-turn Based Therapeutic Agents , 2003 .

[121]  Leland J. Gershell,et al.  A brief history of novel drug discovery technologies , 2003, Nature Reviews Drug Discovery.

[122]  Gordon L Amidon,et al.  A Mechanistic Approach to Understanding the Factors Affecting Drug Absorption: A Review of Fundamentals , 2002, Journal of clinical pharmacology.

[123]  Stephen R. Johnson,et al.  Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.

[124]  C. Soto,et al.  Converting a peptide into a drug: strategies to improve stability and bioavailability. , 2002, Current medicinal chemistry.

[125]  W. Delano Unraveling hot spots in binding interfaces: progress and challenges. , 2002, Current opinion in structural biology.

[126]  R. Egleton,et al.  Peptide drug modifications to enhance bioavailability and blood-brain barrier permeability , 2001, Peptides.

[127]  H. Kessler,et al.  Design and Synthesis of Potent and Selective a 4 7 Integrin Antagonists , 2001 .

[128]  P. Nelson,et al.  A novel mechanism for chaperone-mediated telomerase regulation during prostate cancer progression. , 2001, Cancer research.

[129]  D. Moody,et al.  Variables in human liver microsome preparation: impact on the kinetics of l-alpha-acetylmethadol (LAAM) n-demethylation and dextromethorphan O-demethylation. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[130]  H. Saito,et al.  Structural requirements for determining the substrate affinity of peptide transporters PEPT1 and PEPT2 , 2000, Pflügers Archiv.

[131]  A. Bogan,et al.  Anatomy of hot spots in protein interfaces. , 1998, Journal of molecular biology.

[132]  N. Krause Copper-Catalyzed Enantioselective Michael Additions: Recent Progress with New Phosphorus Ligands. , 1998, Angewandte Chemie.

[133]  N. Krause Kupferkatalysierte enantioselektive Michael‐Additionen: jüngste Fortschritte mit neuen Phosphorliganden , 1998 .

[134]  M. Rashidi,et al.  In vitro oxidation of famciclovir and 6-deoxypenciclovir by aldehyde oxidase from human, guinea pig, rabbit, and rat liver. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[135]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[136]  Ismael J. Hidalgo,et al.  Carrier-mediated transport and efflux mechanisms in Caco-2 cells , 1996 .

[137]  L. Presta,et al.  Mucosal addressin cell adhesion molecule-1: a structural and functional analysis demarcates the integrin binding motif. , 1996, Journal of immunology.

[138]  S. Clarke,et al.  Role of aldehyde oxidase in the in vitro conversion of famciclovir to penciclovir in human liver. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[139]  T. Clackson,et al.  A hot spot of binding energy in a hormone-receptor interface , 1995, Science.

[140]  L. Benet,et al.  Pharmacokinetics of Famciclovir in Man , 1993 .

[141]  R. Hodge Famciclovir and Penciclovir. The Mode of Action of Famciclovir Including Its Conversion to Penciclovir , 1993 .

[142]  L Wang,et al.  Peptoids: a modular approach to drug discovery. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[143]  H. Bundgaard The utility of the prodrug approach to improve peptide absorption , 1992 .

[144]  Ruth F. Nutt,et al.  A potent cyclic hexapeptide analogue of somatostatin , 1981, Nature.

[145]  G. Levy Clinical pharmacokinetics of salicylates: a re-assessment. , 1980, British journal of clinical pharmacology.

[146]  Nicole J. Yang,et al.  Getting across the cell membrane: an overview for small molecules, peptides, and proteins. , 2015, Methods in molecular biology.

[147]  T. Hoffmann,et al.  Peptide therapeutics: current status and future directions. , 2015, Drug discovery today.

[148]  C. Cabañas,et al.  CXCR7 impact on CXCL12 biology and disease. , 2013, Trends in molecular medicine.

[149]  R. Kineman,et al.  Somatostatin and its receptors contribute in a tissue-specific manner to the sex-dependent metabolic (fed/fasting) control of growth hormone axis in mice. , 2011, American journal of physiology. Endocrinology and metabolism.

[150]  W. Hooper,et al.  Metabolism of diazepam and related benzodiazepines by human liver microsomes , 2010, European Journal of Drug Metabolism and Pharmacokinetics.

[151]  K. Pang,et al.  DMD #15321 Permeability, Transport, and Metabolism of Solutes in Caco-2 Cell Monolayers: A Theoretical Study , 2007 .

[152]  Daniel R. Caffrey,et al.  Structure-based maximal affinity model predicts small-molecule druggability , 2007, Nature Biotechnology.

[153]  David C Fry,et al.  Protein-protein interactions as targets for small molecule drug discovery. , 2006, Biopolymers.

[154]  J. Lötsch Opioid metabolites. , 2005, Journal of pain and symptom management.

[155]  K. Richter,et al.  Diazepam metabolism in human foetal and adult liver , 2004, European Journal of Clinical Pharmacology.

[156]  K. Luthman,et al.  Correlation of drug absorption with molecular surface properties. , 1996, Journal of pharmaceutical sciences.

[157]  A. Harris,et al.  Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects. , 1994, Gut.

[158]  S. Schreiber,et al.  The mechanism of action of cyclosporin A and FK506. , 1992, Immunology today.

[159]  P. Artursson,et al.  Transport and permeability properties of human Caco-2 cells: An in vitro model of the intestinal epithelial cell barrier , 1990 .

[160]  D. Kell,et al.  Distributed under Creative Commons Cc-by 4.0 the Apparent Permeabilities of Caco-2 Cells to Marketed Drugs: Magnitude, and Independence from Both Biophysical Properties and Endogenite Similarities , 2022 .